XML 74 R54.htm IDEA: XBRL DOCUMENT
v3.20.4

Major Customers and Concentration of Credit Risk (Details) - USD ($) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues | $ 5,580,581 | $ 236,178 | $ 267,187 | $ 1,327,274 | $ 279,488 | $ 866,863 | $ 135,673 | $ 2,829,905 | $ 7,411,220 | $ 4,111,930 | $ 30,481,897
Revenue | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  | 100.00% | 100.00% | 100.00%
ApolloBio |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  | $ 0 | $ 0 | $ 23,000,000
ApolloBio | Revenue | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  | 0.00% | 0.00% | 75.00%
AstraZeneca |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  | $ 170,587 | $ 3,194,877 | $ 6,850,424
AstraZeneca | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  |  |  | 161,000 |  |  |  |  | $ 161,000 |
AstraZeneca | Revenue | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  | 2.00% | 78.00% | 23.00%
AstraZeneca | Accounts Receivable | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  |  | 23.00% |
Advaccine |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  | $ 5,000,000 | $ 0 | $ 0
Advaccine | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Accounts receivable | 7,100,000 |  |  |  |  |  |  |  | $ 7,100,000 |  |
Advaccine | Revenue | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  | 68.00% | 0.00% | 0.00%
Advaccine | Accounts Receivable | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  | 38.00% |  |
Plumbline Life Sciences, Inc. |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  | $ 1,370,396 | $ 0 | $ 0
Plumbline Life Sciences, Inc. | Revenue | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  | 18.00% | 0.00% | 0.00%
All other, including affiliated entities |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  | $ 870,237 | $ 917,053 | $ 631,473
All other, including affiliated entities | Revenue | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  | 12.00% | 22.00% | 2.00%
DoD | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Accounts receivable | $ 11,400,000 |  |  |  |  |  |  |  | $ 11,400,000 |  |
DoD | Accounts Receivable | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  | 62.00% |  |
MCDC | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  |  |  | $ 469,000 |  |  |  |  | $ 469,000 |
MCDC | Accounts Receivable | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  |  | 67.00% |

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(5)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ConcentrationRiskLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=ino_ApolloBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=ino_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=ino_AdvaccineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=ino_AllOtherCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=ino_DoDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=ino_MCDCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |